source
- FDA approves vepdegestrant for ESR1-mutated ER-positive advanced breast cancerOn May 1, 2026 the FDA gave its first approval to vepdegestrant, an oral selective estrogen receptor degrader, for adult patients with estrogen receptor-positive, HER2-negative breast cancer that c…
- FDA grants breakthrough therapy designation to Emi-Le for advanced adenoid cystic carcinomaThe U.S. Food and Drug Administration has granted breakthrough therapy designation to Emi-Le for patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). Phase 1 tri…